AlzeCure Publishes its Interim Report for Q1 2020

AlzeCure Publishes its Interim Report for Q1 2020

PR Newswire

STOCKHOLM, May 5, 2020

STOCKHOLM, May 5, 2020 /PRNewswire/ -- AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the first quarter of 2020 is now available on the company's website:

Financial information for the first quarter, 2020           

Significant events during the first quarter, 2020           

Significant events after the end of the period           

Read the full report at: 

The information was submitted for publication, through the agency of the contact person set out below at 08.00 am CET on May 5, 2020. 

About AlzeCure Pharma

AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in innovative drug research and development with a primary focus on Alzheimer's disease and pain. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms within the Alzheimer area, NeuroRestore® and Alzstatin®. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury, sleep apnea and Parkinson's disease. The company also has a research platform in the field of pain, Painless, with two projects, TrkA-NAM and VR1/ACD440. FNCA Sweden AB, +46(0)8-528-00-399,, is the company's certified adviser. For further information, please visit our website at

For more information, please contact

Martin Jönsson, CEO
Tel: +46 (0)70-786-94-43

This information was brought to you by Cision,c3103483

The following files are available for download:


Martin Jönsson


Voltar noticias em Inglês